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• Anxiety is common in bipolar spectrum disorders and associated with poor outcomes.
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• CBT for comorbid anxiety disorders appears promising in pilot studies.
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Cognitive behaviour therapyComorbid anxiety is common in bipolar spectrum disorders [BPSD], and is associated with poor outcomes. Its
clinical relevance is highlighted by the “anxious distress speciﬁer” in the revised criteria for Bipolar Disorders
in the Diagnostic and Statistical Manual 5th Edition [DSM-5]. This article reviews evidence for the effectiveness
of psychological therapy for anxiety in adults with BPSD (bipolar I, II, not otherwise speciﬁed, cyclothymia, and
rapid cycling disorders). A systematic search yielded 22 treatment studies that included an anxiety-related out-
comemeasure. Cognitive behavioural therapy [CBT] for BPSD incorporating an anxiety component reduces anx-
iety symptoms in cyclothymia, “refractory” and rapid cycling BPSD, whereas standard bipolar treatments have
only a modest effect on anxiety. Preliminary evidence is promising for CBT for post-traumatic stress disorder
and generalised anxiety disorder in BPSD. Psychoeducation alone does not appear to reduce anxiety, and data
for mindfulness-based cognitive therapy [MBCT] appear equivocal. CBT during euthymic phases has the greatest
weight of evidence.Where reported, psychological therapy appears acceptable and safe, butmore systematic col-
lection and reporting of safety and acceptability information is needed. Development of psychological models
and treatment protocols for anxiety in BPSD may help improve outcomes.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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Bipolar disorder [BP] is deﬁned as episodes of extreme moods;
mania (or hypomania in BP-II) and depression (American Psychiatric
Association [APA], 2013a). It has a lifetime prevalence of around 1%
(Merikangas et al., 2011). Bipolar spectrumdisorders [BPSD] additional-
ly include BP Not Otherwise Speciﬁed [NOS], which does not clearly fall
within the BP-I or II criteria, and cyclothymia (recurrent episodes of hy-
pomania and minor depressive episodes, thought to be a symptomati-
cally mild, yet chronic, type of BPSD), and all forms can present as
rapid cycling BP (four or more acute episodes per year), a further chal-
lenge to treatment and prognosis. Medical management is complex
and around 60% of patients relapse within 2 years of remission from a
major depressive or manic episode (Geddes & Miklowitz, 2013). Poor
outcomes are associated with early age of onset, delay in diagnosis
and treatment, presence of residual symptoms, and comorbidities in-
cluding subsyndromal anxiety (Perlis et al., 2006; Treuer & Tohen,
2010). Amore detailed consideration of anxiety and its treatmentwith-
in BPSD is clearly warranted.
Psychosocial stressors are implicated in the onset of BPSD episodes
(Ghaemi, Boiman, & Goodwin, 1999) and psychosocial interventions
are increasingly emphasised in clinical guidance (Goodwin, 2003;
Hirschfeld et al., 2004; National Institute for Health & Clinical
Excellence [NICE], 2014). The need for close integration between
psychological/psychosocial and pharmacological approaches, with psy-
chological intervention adjunctive to long-term maintenance pharma-
cotherapy, is now well recognised (Goodwin & Consensus Group of
the British Association for Psychopharmacology, 2009). Although
psychoeducation is beneﬁcial and possibly more cost-effective than
structured psychological treatment in terms of relapse prevention
(Geddes&Miklowitz, 2013), there is also evidence that all psychological
therapies outperform psychoeducationwhen global functioning ismea-
sured alongside clinical outcome (Miklowitz et al., 2007).1.1. Treatment of BPSD
Cognitive behaviour therapy [CBT] has been developed for BPSD
based on protocols for major depression, but results frommajor clinical
trials remain inconclusive (Lam, Hayward, Watkins, Wright, & Sham,
2005; Parikh et al., 2012; Scott et al., 2006). Overall, the weight of evi-
dence ﬁnds little or no beneﬁt of existing CBT protocols for relapse pre-
vention (Lynch, Laws, & McKenna, 2010; Szentagotai & David, 2010).
Consequently there has been increasing interest in innovating and
improving CBT for BPSD, driven by development of novel cognitive
theories (e.g. Holmes, Geddes, Colom, & Goodwin, 2008; Johnson,
2005; Jones, 2001; Mansell, Morrison, Reid, Lowens, & Tai, 2007),
qualitative research (Mansell, Powell, Pedley, Thomas, & Jones,
2010), and single case series (Mansell, 2007; Searson, Mansell,
Lowens, & Tai, 2012).
There are several possibilities for improving therapeutic strategies,
for example, achieving a better characterisation of the BPSD phenotypes
and maintaining mechanisms, and measuring treatment effectiveness
not solely by acute relapse rate, but by including maintenance of
inter-episodic daily mood stability, patients' global psychosocial func-
tioning, coping strategies and life satisfaction (Geddes & Miklowitz,
2013). Novel approaches have recently recommended “staging” the dif-
ferent phases of BPSD to better address the speciﬁc presenting needs
and dysfunction. The prodromal stage is characterised bymild unspecif-
ic mood symptoms, high rates of nonspeciﬁc anxiety, and additional bi-
polar risk factors. The ﬁrst acute mood episode stage may also include
signiﬁcant anxiety symptoms, and later stages are characterised by
subsyndromal symptoms and syndromal relapses despite treatment,
e.g. with more prominent cognitive impairment (Kapczinski et al.,
2014; Scott et al., 2013). Psychological interventions such as CBT
would be indicated for early stages (Berk et al., 2013) or for addressing
later residual symptoms (Cosci & Fava, 2012; Fava, Bartolucci, Rafanelli,
& Mangelli, 2001).
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Comorbid anxiety can be debilitating in itself and prevalence within
BPSD is high. Lifetime comorbidity is estimated between 24% (Henry
et al., 2003) and 74.9% (Merikangas et al., 2007). Around one third of
BP-I and II patientsmeet criteria for an anxiety disorder, most common-
ly social anxiety (22.0% lifetime; 12.7% current), panic disorder with or
without agoraphobia (17.3%; 8.0%), obsessive-compulsive disorder
[OCD] (9.9%; 5.7%), post-traumatic stress disorder [PTSD] (17.2%;
5.1%), agoraphobia without panic (8.5%; 4.4%), and generalised anxiety
disorder [GAD] (18.4%; 2.3%) (Otto et al., 2006; Simon et al., 2004), see
McIntyre, Soczynska, et al. (2006) for a detailed review.
Comorbid anxiety has been linked to a range of poor outcomes such
as illness severity (Lee & Dunner, 2008), suicide attempts (Goldberg &
Fawcett, 2012), lower quality of life (Kauer-Sant Anna et al., 2007),
and physical ill-health (Albert, Rosso, Maina, & Bogetto, 2008), for re-
views see El-Mallakh and Holliﬁeld (2008) and McIntyre, Konarski,
et al. (2006). Anxiety has been described as a “clinicallymeaningful cor-
relate of poor outcome in the acute treatment of bipolar I disorder”
(Feske et al., 2000, p.961). This evidence has led to the introduction of
a new diagnostic speciﬁer in the Diagnostic and Statistical Manual 5th
Edition [DSM-5] (APA, 2013a), described as an “anxious distress speciﬁ-
er”. The aim is to identify patients with BPSD with anxiety symptoms
that are additional to the BPSD criteria (APA, 2013b) and that may be
effectively targeted with speciﬁc interventions. For example, recent
data suggests that the presence of anxiety could indicate good response
to adjunctive psychological treatment for acute BPSD depression
(Deckersbach et al., 2013). Moreover, prodromes and early stages of
BPSD appear to be particularly characterised by high levels of anxiety,
which may represent an important target for successful early interven-
tion strategies (Duffy et al., 2013).
Unlike BPSD, there is clear evidence that (non-comorbid) anxiety
disorders can be treated effectively with CBT. For example, the UK Na-
tional Institute of Health and Clinical Excellence [NICE], a government-
funded, independent body that considers the cost-effectiveness of treat-
ments and makes recommendations for health services, recommends
CBT as a ﬁrst-line intervention for GAD and panic with/without agora-
phobia (NICE, 2011), PTSD (NICE, 2005b), OCD (NICE, 2005a), and social
anxiety disorder (NICE, 2013). A review of meta-analyses of RCTs found
medium to large effect sizes for CBT for several anxiety disorders
(Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012), and meta-analyses
of clinically-representative effectiveness studies suggest the results
generalise to clinical settings (Hans & Hiller, 2013; Stewart &
Chambless, 2009).
For people with BPSD and comorbid anxiety, current guidance rec-
ommends “treatment in line with the relevant NICE clinical guideline,
in addition to treatment for bipolar disorder” (NICE, 2014, p.15). How-
ever, there are no established protocols for treating anxiety in BPSD,
and people with BPSD are routinely excluded from anxiety treatment
studies (Hoertel, Le Strat, Blanco, Lavaud, & Dubertret, 2012). The
need for a well-established evidence-based psychological treatment
for anxiety in BPSD is therefore urgent, particularly given the current
heated debate around the use of anti-anxiety pharmacological interven-
tions in BPSD (Goodwin & Consensus Group of the British Association
for Psychopharmacology, 2009; Vázquez, Baldessarini, & Tondo, 2014).
Pharmacological options for anxiety disorders include benzodiazepines,
whose efﬁcacy has recently been revisited (Balon, 2013; Ofﬁdani, Guidi,
Tomba, & Fava, 2013; Rickels, 2013) although their potential for abuse
and dependence remains highly controversial. The other most common
option is selective serotonin reuptake inhibitor [SSRI] antidepressants,
which can be difﬁcult to manage and may worsen the course of BPSD
(Pacchiarotti et al., 2013). For example, studies have reported the risk
of a “treatment emergent affective switch” in BPSD patients treated
with SSRIs (Post et al., 2006; Tondo, Vázquez, & Baldessarini, 2010). De-
velopment of excessive arousal or worsening of impulsivity and irrita-
bility symptoms by SSRI treatment could be particularly problematicin youth BPSD populations with anxiety (Ofﬁdani, Fava, Tomba, &
Baldessarini, 2013; Strawn et al., 2013). Mood stabilisers include lithi-
um, anticonvulsants and antipsychotics and are the recommended
medication for acute and long term treatment of BPSD (NICE, 2014).
They can reducemood oscillations of both polarities and initial evidence
suggests some beneﬁcial effects on anxiety, for example the antipsy-
chotic quetiapine used for BPSD depression. However, further systemat-
ic assessment is needed to develop clear clinical guidelines (Vázquez
et al., 2014).
Thus, it is unclear how clinicians should best proceed in tackling the
debilitating, and commonly untreated, comorbidity of BPSD and
anxiety.
1.3. Objectives and importance of the current review
This review aims to identify, synthesise, and critically evaluate re-
search on the psychological treatment of anxiety within BPSD. The re-
cent inclusion of the anxious distress speciﬁer in DSM-5 highlights
increased recognition of the problem posed by anxiety in BPSD. Similar-
ly, a study protocol has recently been published testing a speciﬁc inter-
vention developed for anxiety in BPSD (Jones et al., 2013) suggesting
that such a review is timely. While there are previous reviews in this
area (Provencher, Hawke, & Thienot, 2011; Rakofsky & Dunlop, 2011),
they have included only a small number of studies (11 in total) and
given predominantly a narrative account. The current review provides
an advance by identifying and including a further 11 studies, and
using an established systematic review methodology with a critical
evaluation of research methods and outcomes. The review is guided
by the Cochrane Collaboration's (2011) handbook and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA]
checklist (Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group,
2009). The current review aims to ascertain, in BPSD populations, how
effectively comorbid anxiety disorders and/or anxiety symptoms are re-
duced by psychological therapy:
• designed speciﬁcally to target BPSD anxious distress,
• targeting both anxiety and BPSD mood symptoms using a combined
approach,
• targeting comorbid anxiety disorders only in BPSD populations, or
• targeting BPSD mood symptoms only.
2. Method
Titles and abstracts in AMED, EMBASE, HMIC, MEDLINE, PsycINFO,
BNI, CINAHL, andHEALTHBUSINESS ELITE databaseswere systematical-
ly searched on 16/05/2013, using terms related to BPSD, anxiety, and
psychological therapy (see Appendix A). Thiswas augmented by aman-
ual search using reference lists of related papers, contacting researchers,
and Google Scholar internet searches. Due to the heterogeneity of the
studies a formal synthesis (i.e. meta-analysis) was not possible. Instead,
a systematic review was conducted, using the principles cited above.
2.1. Inclusion criteria
Studieswere included if (1) participants included people with BPSD,
(2) pre–post outcome data related to anxiety (e.g. symptom measures
or diagnostic interviews)were reported, (3) treatment targeted anxiety
and/or BPSD, and (4) the paper was published in a peer-reviewed
journal.
2.2. Exclusion criteria
No limitations were placed on year or language of publication (al-
though searches were in English). Theoretical papers, those including
children and/or adolescents, or with a distinctly different treatment
focus (e.g. addiction, eating disorders), were excluded.
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Fig. 1 provides a ﬂow-chart for the selection of eligible studies. Ten
eligible studies were identiﬁed from previous reviews (Baer,
Minichiello, & Jenike, 1985; Dusser, Romo, & Leboyer, 2009; Hamblen,
Jankowski, Rosenberg, & Mueser, 2004; Miklowitz et al., 2009; Mueser
et al., 2007, 2008; Rosenberg, Mueser, Jankowski, Salyers, & Acker,
2004; Van Gent, 2000; Van Gent & Zwart, 1993b; Williams et al.,
2008). One of these papers (Van Gent, 2000) provides follow-up data
only, leaving nine studies.
Seven further studies were identiﬁed through a systematic liter-
ature search using the criteria speciﬁed above (Da Costa et al., 2011;
Docteur, Mirabel-Sarron, Guelﬁ, Rouillon, & Gorwood, 2013;
González-Isasi et al., 2010; Perich, Manicavasagar, Mitchell, Ball, &
Hadzi-Pavlovic, 2013; Proudfoot et al., 2012; Satterﬁeld, 1999;
Totterdell, Kellett, & Mansell, 2012).
Manual searching identiﬁed eight further eligible papers (Docteur
et al., 2007; Fava, Rafanelli, Tomba, Guidi, & Grandi, 2011; González
Isasi, Echeburúa, Limiñana, & González-Pinto, 2012; Lu et al., 2009;
Reilly-Harrington et al., 2007; Thienot, Provencher, & St-Amand, 2013;
Van Gent, Vida, & Zwart, 1988; Van Gent & Zwart, 1993a). Two of
these papers (González Isasi, Echeburúa, Limiñana & González-Pinto,
2012; Van Gent & Zwart, 1993a) provide follow-up data only, leaving
six studies.15 excluded: not s
population
Titles and abstracts
screened for eligibility
109 studies identified
through literature search
10 screened in full
67 excluded: not t
studies
16 excluded: not t
of interest
1 excluded: unpub
conference abstra
1 excluded: no an
data
1 excluded: not a
treatment study
8 eligible studies identified by
literature search
6 eligible studies identified by
manual search
9 eligible studies identified by
previous reviews
Fig. 1. Flow-chart for the seleThe 22 included studies are summarised in Table 1.
Table 1 includes details of sample age, location; anxiety type and
BPSD type; participants' mood at the time of intake and any exclusion
criteria; the psychological treatment; and the study design. Three
types of treatment approach are delineated: treatments that target
both anxiety and BPSD symptoms; treatments that target speciﬁc anxi-
ety disorders in a BPSD population; and treatments that primarily target
BPSD symptoms and additionally report anxiety outcomes. No treat-
ment studies were found speciﬁcally designed to target BPSD anxious
distress (or a comparable construct).
3.1. Summary of study characteristics
3.1.1. Participants
All studies recruited participants between episodes except
Proudfoot et al. (2012), which recruited newly diagnosed patients of
whom48%were euthymic at intake according to self-report. The studies
varied in how symptom remissionwas deﬁned, andmost included peo-
ple experiencing some mood symptoms. This reﬂects the growing ac-
knowledgement that the course of BPSD is rarely one of discrete
episodes with full symptom remission between, but that patients fre-
quently experience signiﬁcant mood symptoms or mood instability
inter-episode. Few studies report ethnicity, though where it is reported
the large majority of participants are Caucasian, except Lu et al. (2009),pecified
reatment
reatment
lished
ct
xiety
10 did not include BP
3 adolescent/child studies
1 no anxiety measure
1 excluded axis 1
comorbidites
8 medication only
5 other treatment focus
3 other intervention
1 duplicate removed
22 studies for inclusion
ction of eligible studies.
23H.J. Stratford et al. / Clinical Psychology Review 35 (2015) 19–34where 42% were European-American, 37% African-American, 11%
Hispanic, and 11% Other. Results may not be generalizable to younger
(under 18 years) and older (over 65 years) adults given that child and
adolescent studies were excluded and no older adult studies were
found. Notably, all the studies suggest complexity in the participants'
presentations; for example, comorbidity, multiple episodes, persistent
symptoms, risk/suicide history, and social/functional impairment. This
suggests good ecological validity in relation to clinical populations.
3.1.2. Interventions
The majority of studies (14/22) used CBT with between six and 21
sessions, of which eight were individual- and six group-based interven-
tions (Table 1). Three studies employed Mindfulness Based Cognitive
Therapy [MBCT] in groups, two psychoeducation in groups, one
psychoeducation via an online programme, and one Exposure and Re-
sponse Prevention [ERP] on an individual basis. Fava et al. (2011) se-
quentially applied CBT and wellbeing therapy [WBT]. All used an
established (if adapted) manual except Dusser et al. (2009) and
Satterﬁeld (1999). Two studies included family members (Baer et al.,
1985; Da Costa et al., 2011). All studies but one expected patients to
continue with mood-stabilising medication, and the majority of partic-
ipants were takingmedication including lithium, neuroleptics, anticon-
vulsants, antidepressants, and/or anxiolytics. Some studies did not
systematically collect/report information on medication use (Lu et al.,
2009; Mueser et al., 2008; Rosenberg et al., 2004; Thienot et al., 2013).
Changes tomedicationwere reported during the study for 18/95 partic-
ipants in Perich et al. (2013), and 2/6 in Reilly-Harrington et al. (2007).
In the study by Fava et al. (2011), patients usingmood stabilisers or an-
tidepressants were excluded, and participants were titrated off benzo-
diazepines, constituting a distinct population compared to the other
studies.
3.1.3. Outcomes
Most studies assessed self- or clinician-reported anxiety symptoms
using continuous measures, e.g. Beck Anxiety Inventory [BAI] (Beck &
Steer, 1993), State-Trait Anxiety Inventory [STAI] (Spielberger, Gorsuch,
& Lushene, 1970). Seven focussed on a single anxiety diagnosis;
e.g. GAD (Thienot et al., 2013), and a further two onmixed anxiety disor-
ders (Fava et al., 2011; Reilly-Harrington et al., 2007).
3.1.4. Study design
Seven of the 22 studies comprise randomised controlled trials [RCTs].
Three RCTs report using intent-to-treat analysis [ITT] (Fava et al., 2011;
Mueser et al., 2008; Perich et al., 2013). Two of the RCTs have longer
term outcomes; two years (Fava et al., 2011), and ﬁve years (González
Isasi et al., 2012). Van Gent and Zwart (1993a) and Van Gent (2000)
have ﬁve year follow-ups, but do not collect anxiety data.
Ten are pilot studies, and may be precursors to larger feasibility
studies and RCTs. Three include a comparison group but no random-
ization or blinding, and seven have no comparison group. Pilot stud-
ies are thought to have a risk of selection bias, information bias, and
systematic confounds due to non-randomisation, but may also con-
fer better external validity than RCTs due to the type of population
included (Grimes & Schulz, 2002). Those without blinding and
with only clinician-rated measures are especially at risk of bias
(e.g. Docteur et al., 2013). Most of the pilot studies report only
data from those participants who completed treatment, (or failed
to specify) except Mueser et al. (2007), which used ITT, and
Miklowitz et al. (2009), which imputed missing data with the
sample's mean score.
Five studies used single-case designs. Three beneﬁt fromexperimen-
tal AB designs, either establishing a stable baseline (Thienot et al., 2013)
or – given that instability is the key feature of BP – a multiple baseline
design that characterises the typical instability (Satterﬁeld, 1999;
Totterdell et al., 2012). Two are narrative case reports (Baer et al.,1985; Hamblen et al., 2004), which increases the risk of bias. The
small sample sizes in all these studies limit generalisability.
Table 2 provides an overview of the key ﬁndings, summarises the re-
sults, and details drop-out rates for each study. Studies are now
reviewed in turn, according to the three categories of treatment
outlined above.
3.2. Treatments that include components targeting both anxiety
and BPSD (N = 7)
3.2.1. Randomised controlled trials
Three RCTs were identiﬁed, all of which included blind assessment
and follow-ups, of ﬁve years (González-Isasi, et al., 2010; González
Isasi, et al., 2012), two years (Fava et al., 2011), and one year (Perich
et al., 2013). Two (Fava et al., 2011; Perich et al., 2013) used concealed
randomisation, ITT, and an active control (clinical management with
equal contact time; TAU plus written psychoeducation resources,
respectively).
González-Isasi, et al. (2010) and González Isasi, et al. (2012) N=42
RCT evaluated CBT for BPSD based on the protocol by Lam et al. (2010)
with the addition of “relaxation and breathing, self-instruction and cog-
nitive distraction” to target anxiety symptoms. Participants had “refrac-
tory” BP-I and II; persistent, treatment-resistant affective symptoms,
although “patients with poor medication adherence, according to the
doctor or relatives' report, were excluded” (González Isasi et al., 2012,
p.135). Retention was 100%, and the control group remained free from
therapy for the entire ﬁve years, while the “psychiatrist provided sup-
port when necessary” (p.82). Within-groups, there was signiﬁcant im-
provement in the treatment group, and deterioration in the TAU
group, in state anxiety. Between-groups, there were signiﬁcant differ-
ences in state anxiety at follow-up (6 months, 12 months, and 5
years). This study suggests that CBT for BPSDwith an additional anxiety
management component can reduce anxiety and improve other out-
comes in the long term.
Fava et al.'s (2011) N = 62 RCT sequentially applied CBT to target
phobic anxiety (Marks, 1987) and depression (Basco & Rush, 1996),
and thenWBT for hypomania.WBT aims to increase autonomy, person-
al growth, environmentalmastery, purpose in life, positive relationships
with others and self-acceptance (based on Ryff, 1989), thereby
substituting hypomania with sustained well-being. It does not include
psychoeducation, medication adherence or social rhythm therapy
(Fava, 1999; Fava & Tomba, 2009). Participants had cyclothymia and,
notably, were not taking mood stabilising/antidepressant medica-
tion and were titrated off benzodiazepines during treatment. The
treatment group had signiﬁcantly higher levels of affective symp-
toms than the control group at intake but were otherwise matched.
Comorbidities were various anxiety disorders, hypochondriasis
(health anxiety) and body dysmorphic disorder. There was a signiﬁ-
cant reduction in comorbid diagnosis rates, maintained at two years,
and a signiﬁcant group-by-time interaction, suggesting that CBT/
WBT effectively reduced comorbid anxiety disorders compared to
the control condition.
Perich et al.'s (2013) N = 95 RCT adapted the eight week MBCT
course (Segal, Williams, & Teasdale, 2002) for BP-I and II to include
awareness of mania and anxiety prodromes in addition to depres-
sion and suicidal thoughts. Attrition was high, with only 34 partici-
pants (36%) completing the ﬁnal follow-up (22 MBCT, 12 TAU). A
signiﬁcant condition-by-time interaction suggested that MBCT re-
duced state anxiety compared to the control condition. Similar
trend-level improvements were found for trait anxiety and stress.
Comorbid anxiety diagnosis rates fell in both groups, but with no
signiﬁcant between-group difference at one year. MBCT modestly
reduced state anxiety and stress, but did not appear to reduce diag-
nosis rates (nor affective symptoms) compared to TAU. The high rate
of attrition means that these results must be interpreted with
caution.
Table 1
Study characteristics.
N,Mean age
Location
Anxiety type
BPSD type
Mood at intake/exclusions Intervention Study design
Treatments that include components targeting both anxiety and BPSD (N = 7)
Dusser et al.
(2009)
N = 10
18+ mean age 47
France.
Continuous anxiety symptoms (“stress”).
BP-I & II between episodes.
Patients with current melancholic depression or
(hypo)mania were excluded (not operationalised).
Mean baseline scores: BDI-13 5.4 (mild), MADRS 5,
MRS 1.87
Group CBT for BPSD (novel approach).
6× 2 h weekly sessions.
Pilot.
No comparison group.
6 month f'up.
Fava et al. (2011) N = 62
18–65
Italy.
Mixed anxiety diagnoses (In order of prevalence in CBT/
WBT vs. CM: GAD 3 vs. 5; panic & agoraphobia 5 vs. 2;
OCD 4 vs. 2; social anxiety 4 vs. 2; agoraphobia 1 vs. 3;
panic disorder 4 vs. 0; BDD 2 vs. 1; health anxiety 2 vs. 1;
and simple phobias 2 vs. 1.)
Cyclothymia.
Excluded medication within last 2 years..
Cyclothymia diagnosis, i.e. no history of major
depression or mania (SADS). No min/max mood scores,
mean modiﬁed CID score at intake CBT/WBT 42.32, CM
36.87; MAS 9.26, 9.19.
Group/Indiv (not known) CBT then WBT
(Fava, 1999; Fava & Tomba, 2009), included
anxiety module (novel approach).
10× 45 min fortnightly sessions.
RCT vs. “Clinical management”
(active control).
Concealed randomisation.
2 year f'up. Blind raters.
González-Isasi, et al.
(2010) and González
Isasi, et al. (2012)
N = 42
18–65
Spain.
Continuous anxiety symptoms.
“Refractory” BP-I & II (≥2 relapses within 1 yr, suicide
attempts, social-occupational difﬁculties, or persistent
affective symptoms deﬁned by more than 3 months
BDIN7 and/or YMRSN6) between episodes.
Patients euthymic or with subsyndromal symptoms at
intake (BDI N 7; YMRS N 6), max score not speciﬁed.
Mean baseline scores BDI, 11.06 (mild) TAU, 11.05 CBT,
YMRS 2.06 TAU, 2.50 CBT.
Group CBT for BP (Lam et al., 1999) plus
additional anxiety module.
20× 1.5 h weekly groups of 10.
RCT vs. TAU.
Blind assessment.
5 year f'up.
Miklowitz et al.
(2009)
N = 22
Mean age 41
US & UK.
Continuous anxiety symptoms.
BP-I & II between episodes.
BP-I or II “currently in remission” using MINI. A full-blown
episode within last 2 years but onset not within 3 months
of trial start. Subsyndromal symptoms not excluded. Min/
max scores not speciﬁed.
Group MBCT (Segal et al., 2002) included
anxiety/mania prodromes.
8× 2 h weekly groups of 7–15.
Pilot.
No comparison group, non-
blinded.
No follow-up
Perich et al.
(2013)
N = 95
18+ (mean age not
reported)
Australia.
Continuous anxiety symptoms.
BP-I & II between episodes.
Current DSM-IV major depressive, hypomanic or manic
episode (using SCID) were excluded. Mean intake
scores: MADRS 11.71 MBCT, 14.97 TAU; YMRS 4.98
MBCT, 5.47 TAU; DASS depression 14.79 MBCT, 19.5
TAU.
Group MBCT (Segal et al., 2002) included
anxiety/mania prodromes.
8× 2–2.5 h weekly groups of 4–8.
RCT vs. TAU (+ written
psychoed'n).
Concealed, computerised,
randomisation. Blind raters.
Fidelity checks.
12 month f'up.
Reilly-Harrington
et al. (2007)
N = 10
Mean age 38
US.
Mixed anxiety diagnoses, continuous anxiety
symptoms.
Rapid-cycling BP-I, between episodes.
Current manic or mixed episode were excluded (using
SCID). Mean intake scores: MADRS 22.67, YMRS 13.5.
CBT for BPSD (Newman, Leahy, Beck, Reilly-
Harrington, & Gyulal, 2001)with anxietymodule
(e.g. Barlow & Craske, 2006).
20x 50 min weekly sessions, booster at 4 weeks.
Pilot.
No comparison group.
8 week f'up.
Satterﬁeld (1999) N = 1
33
US.
Continuous anxiety symptoms.
Rapid cycling BP-I.
No raw data for BDI or YMRS presented. Scores at
intake indicated moderate depression (using BDI
cutoffs).
CBT for rapid cycling BPSD (novel approach).
Weekly➔monthly sessions for 12 months.
AB single case design. No multiple
baseline assessment.
Treatments that target speciﬁc anxiety disorders in a BPSD population (N = 7)
Baer et al. (1985) N = 2
37 & 45
US.
OCD.
Mania only and BP-I Between episodes.
Not speciﬁed ERP for OCD.
30–51 sessions biweekly, on-going at
publication.
Case study
No comparison group or baseline.
15 month f'up.
Hamblen et al.
(2004)
N = 3 (n = 1 BP).
Mean age 39
US.
PTSD.
BPSD type not speciﬁed.
“Severe depression” using BPRS, raw score not
reported. Manic symptoms not assessed.
CBT for PTSD.
(Mueser et al., 2004).
12 sessions over 10 weeks.
Case study.
No comparison, no stable baseline.
3 month f'up
Lu et al. (2009) N = 14 (n BPSD not
reported).
Mean age 42
US “ethnically diverse”.
PTSD.
BPSD type not speciﬁed.
Mean BDI-II score at intake: 31.14. Manic symptoms
not assessed. Data not presented separately for BPSD
participants.
CBT for PTSD.
(Mueser et al., 2004).
12–16× 1 h weekly sessions
Pilot replication.
No comparison group. Fidelity
checks.
6 month f'up.
Mueser et al.
(2007)
N = 80 (n = 7 BPSD).
Mean age 43
US.
PTSD.
BPSD type not speciﬁed.
Mean BDI score at intake: 31.07 (total sample); 29.97
(treatment completers); 34.74 (dropouts) ns. Manic
symptoms not assessed. Data not presented separately
for BPSD participants.
Group CBT for PTSD. (Mueser et al., 2004).
21 sessions, groups of 6–8.
Pilot.
No comparison group.
Fidelity checks.
3 month f'up.
Mueser et al. (2008) N = 108 (n = 25 BPSD).
Mean age 44
US.
PTSD.
BPSD type not speciﬁed.
Mean BDI–II score at intake CBT 31.48; TAU 31.76.
Manic symptoms not assessed. Data not presented
separately for BPSD participants.
CBT for PTSD.
(Mueser et al., 2004).
12–16× 1 h weekly sessions.
RCT, vs. TAU.
Concealed, computerised
randomisation. Blind raters.
Fidelity checks.
6 month f'up.
Rosenberg et al.
(2004)
N = 13 (n = 2 BPSD)
Mean age 48
PTSD.
BPSD type not speciﬁed.
Phase of BPSD not speciﬁed. Mean score at intake BPRS
affect subscale 21.33, depression subscale not reported.
CBT for PTSD.
(Mueser et al., 2004).
Pilot.
No comparison group.
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US. Mania symptoms not assessed. Data not provided
separately for BPSD participants.
12–16× 1 h weekly sessions. Non-blinded, uncontrolled.
3 month f'up.
Thienot et al. (2013) N = 4 (n = 2 BP-I, 1 BP-
II, 1 BPSD NOS)
Mean age 49
Canada.
GAD/ high worry.
Mixed BPSD type.
Participants in euthymic phase or subyndromal
symptoms at intake (SCID). Mean scores at intake: BDI-
II 24 +/− 9.2, YMRS 2.3 +/− 3.2.
CBT for GAD (Dugas, 2004).
12× 1 h weekly sessions.
AB multiple baseline single case
series experimental design.
Treatments that target BPSD symptoms only and report anxiety outcomes (N = 8)
Da Costa et al. (2011) N = 41
18–60
Brazil.
Continuous anxiety symptoms.
BP-I & II between episodes.
Currently in episode excluded; “euthymic, mildly
depressed or mildly hypomanic” at intake included
deﬁned using ≥35 BDI, ≥20 YMRS. Mean BDI baseline
score: 19.52 CBT, 11.67 Control (p = .083). Mean YMRS
score 9.68 CBT, 1.33 Control (ns).
Group CBT for BP (Basco & Rush).
14× 2 h weekly sessions, psychoed with
family. Groups of 5–6.
RCT vs. medication only (TAU).
6 month f'up
Docteur et al. (2013) N = 73
(n = 53 CBT, 20 TAU)
18–65, mean age 45
France.
Continuous anxiety symptoms.
BP-I between episodes.
Patients in acute episode excluded (not
operationalised). Mean scores at intake: HAM-D 8.23
(mild), MAS 1.51.
Group CBT for BP (Lam, Jones, Hayward, &
Bright, 1999).
20× 2 h weekly sessions.
Controlled study vs. WL (TAU).
Non-blinded, non-randomised,
clinician-report only.
5–9 month f'up; CBT
m = 8.62 months, SD = 2.66 vs.
WL m = 5.78 months,
SD = 2.63.
Docteur et al. (2007) N = 12 total, but data on
n = 7
18–65, mean age 42
France.
Continuous anxiety symptoms.
BP-I between episodes.
Patients with signiﬁcant symptoms mood symptoms
excluded, not operationalised. No min/max scores
speciﬁed. Mean baseline scores: HAM-D 9 (mild), MAS 2
(no mania), BDI-13 14.5.
Group CBT for BP (Lam et al., 1999).
20× 2 h weekly sessions.
Pilot.
No comparison group, clinician-
report only.
No follow-up
Proudfoot et al. (2012) N = 407
18–75
Australia.
Continuous anxiety symptoms.
BPSD type not speciﬁed. Recruited
within 1 year of diagnosis.
Diagnosed with BPSD (type not speciﬁed) by a health
professional within the past 12 months. Conﬁrmed by
MSQ-27. Mean GADS depression score 6.5. Mania
scores not assessed.
Psychoed: Online Bipolar Education Program,
with/without email contact with Informed
Supporters.
8× 30–40 min weekly modules and
workbooks.
RCT vs. active control (weekly
emails with links to simple BP-
Info).
Participants blind to condition.
High dropout.
6 month f'up.
Totterdell et al. (2012) N = 1
35
UK.
Continuous anxiety symptoms.
Cyclothymia.
Current phase not speciﬁed. Low mood/depression not
assessed. Mean scores during baseline using subjective
1–9 scales: “energetic” 4.73, “happy” 3.57.
CBT for BPSD (adapted Basco & Rush, 2005).
19 sessions weekly.
4× daily monitoring.
AB single case multiple baseline
experimental design.
11 week f'up.
Van Gent et al., 1988;
Van Gent & Zwart,
1993a
N = 34a
Under 60, mean age 40
Netherlands.
Continuous anxiety symptoms.
BPSD type not speciﬁed
Severe depression and acute psychosis excluded (not
operationalised). Phase of BPSD not speciﬁed. Mean
scores at intake: Depression subscale SCL-90, 31.3
group therapy, 25.4 control; cheerful subscale ML 9.6
group therapy, 8.9 control, dispirited subscale 7.1
group therapy, 7.1 control.
Psychoed “group therapy” (Powell, Othmer, &
Sinkhorn, 1977).
10–13× 1.5 h weekly groups of 6–8.
Controlled study vs. TAU.
Non-randomised, non-blinded?
15 month f'up (no anxiety data at
5 year f'up).
Van Gent and Zwart
(1993b), Van Gent,
2000
N = 35–41a
Mean age 42
Netherlands.
Continuous anxiety symptoms.
BPSD type not speciﬁed.
Severe depression and acute psychosis excluded (not
operationalised). Phase of BPSD not speciﬁed. Mean
scores at intake: Depression subscale SCL-90, 31.3
group therapy, 28.5 education group; high mood
subscale ML, 9.6 group therapy, 10.2 education group,
low mood subscale ML, 7.1 group therapy, 2.2
education group.
Psychoed “group therapy” (Van Gent et al.,
1988), vs. Ultra-short psychoed group.
10–13× 1.5 h weekly groups of 6–9. vs. 5×
2.5 h weekly groups of 6–8.
Controlled study, two active
treatment groups.
Non-blinded, non-randomised.
15 month f'up.
Williams et al. (2008) N = 68
(n = 17 BP). Data
presented for N = 55
(n = 14 BP)
18–65
UK.
Continuous anxiety symptoms.
BPSD type not speciﬁed.
History of depression “with serious suicidal ideation or
behaviour” currently in recovery. b1 week “minimal
depression” in last 8 weeks, no manic episode within
6 m (NIMH deﬁnition). Min/max scores not speciﬁed.
Baseline BPSD scores BDI 12.7 MBCT, 11.4 control. No
mania measures.
Group MBCT (Segal et al., 2002).
8× 2 h weekly groups of 12–15, plus full day
meditation practice.
RCT vs. WL (TAU).
Randomisation concealed via
envelopes. Small subgroup
analysis.
No follow-up.
Note.BDD = body dysmorphic disorder, BP-I = bipolar I disorder, BPSD = bipolar spectrumdisorders, CBT = cognitive behaviour therapy, psychoed = psychoeducation, ERP = exposure and responseprevention, F'up = follow-up,GAD = generalised
anxiety disorder, MBCT = mindfulness-based cognitive therapy, ns = non signiﬁcant, NOS = not otherwise speciﬁed, OCD = obsessive compulsive disorder, PTSD = post-traumatic stress disorder, RCT = randomised control trial, TAU = treatment as
usual, WBT = wellbeing therapy.
Measures: BDI = Beck Depression Inventory (Beck, Ward, & Mendelson, 1961); BDI-13 = Beck Depression Inventory short version (Beck & Beamesderfer, 1974); BPRS = Brief Psychiatric Rating Scale (Lukoff, Nuechterlein, & Ventura, 1986);
CID = Clinical Interview for Depression (Guidi, Fava, Bech, & Paykel, 2010); GADS = Goldberg Anxiety and Depression Scale (Goldberg, Bridges, Duncan-Jones, & Grayson, 1988), HAM-D = Hamilton Depression Rating Scale (Hamilton, 1960);
MADRS = The Mongomery Åsberg Depression Scale (Montgomery & Åsberg, 1979); MAS = Mania Scale (Bech, Kastrup, & Rafaelsen, 1986); MINI = Mini International Neuropsychiatric Interview (Sheehan et al., 1998); ML = Mood List
(Zwart & Spooren, 1983), MRS = Mania Rating Scale (Bech, Rafaelsen, Kramp, & Bolwig, 1978);MSQ-27 = Mood Swings Questionnaire (Parker, Hadzi-Pavlovic, & Tully, 2006); NIMH = National Institute of Mental Health; SCL = SymptomCheck-
list (Arrindell & Ettema, 1986; Derogatis, Lipman, Rickels, Uhlenhuth, & Covi, 1974), SCID = Structured Clinical Interview for DSM (First, Spitzer, Gibbon, &Williams, 1996), YMRS = YoungMania Rating Scale (Young, Biggs, Ziegler, &Meyer, 1978).
a Van Gent et al. (1988) compare n = 20 patients in three therapy groups lasting 10 sessions to n = 16WL controls. Van Gent and Zwart (1993a) report an additional 5 year follow-up to the previous study, and present within-group analyses for
n = 26 (no control condition). This paper described four groups sessions lasting 10–13 sessions. Van Gent and Zwart (1993b) compare n = 20 described in Van Gent et al. (1988) to n = 15 from amore recent ultra-short condition. VanGent (2000)
compares n = 26 to n = 15 from the ultra-short condition. It appears as if much of the data is common to the papers, but it is not clearly explained which data is included/excluded in which papers and why. 25
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Table 2
Summary of study ﬁndings.
Results Scores Dropouts
Treatments that include components targeting both anxiety and BPSD (N = 7)
Dusser et al. (2009) ↑STAI-S, ↓STAI-T, ↓HAM-A⁎⁎,
↓PSS14 stress⁎
WG: self-reported stress [PSS14]
pre 36; post 32, p b .05.
HAM-A pre 12; post 4, p b .01.
STAI-S pre 27; post 29, ns.
STAI-T pre 43; post 41, ns
2 dropped out
Fava et al. (2011) ↓SADS diagnosis⁎ BG: nwith Axis 1 comorbidities
Pre 23 CBT/WBT vs. 17 CM, χ2 = 2.536, ns; post: 8 vs. 16,
χ2 = 4.351; 1 yr 8 vs. 16, χ2 = 4.351; 2 yr 6 vs. 15,
χ2 = 5.833, all p b 0.05.
CBT/WBT 5; CM 6.
González-Isasi, et al.
(2010) and González
Isasi, et al. (2012)
↓STAI-S⁎⁎⁎ BG: STAI-S pre: 21.30 CBT vs. 16.80 TAU; post 16.0 vs.
22.35, ns trend p = 0.062; 6 m 16.50 vs. 26.35, p = 0.019;
1 yr 8.85 vs. 32.78, p b 0.001; 5 yr 8.80 vs. 28.55,
p b 0.001.
2 died in control group. No other dropouts
Miklowitz et al. (2009) ↓BAI WG: BAI pre, 15.38; post 12.80 post, Cohen's d = .23 small
effect size. No tests of signiﬁcance are reported due to the
low numbers.
6/22 didn't complete treatment. Complete data for
14/16 treatment completers and 3/6 dropouts.
Perich et al. (2013) ↓STAI-S⁎, ↓STAI-T∞, ↓DASS stress∞,
=DASS anxiety, CIDI diagnosis:
↓WG, =BG
BG: STAI-S pre, 47 MBCT vs. 49 TAU; post, 41 vs. 44; 12 m,
39 vs. 43; F = 2.158, p = 0.048. Diagnosis: pre 69% MBCT
vs. 77% TAU; 12 m 46% vs. 33% χ2 = .083, p = .773
Total dropout 14/48 (29%) MBCT. Deﬁned as
missing more than half the sessions. MBCT: 10/48
(21%) dropped out. TAU: 18/47 (38%) dropped out.
A further 4 (8%) in each group did not complete
f'up. Anxiety outcome data available for 22 MBCT
and 12 TAU.
Reilly-Harrington et al.
(2007)
↓BAI (ns) WG: BAI pre 24.83, moderate; mid 17.33, moderate; post
15.33, mild; 2 m 17.83, moderate. Cohen's d = .55.
Total 4/10 (40%). 3/10 dropped out after 4 or fewer
sessions (of 20 total), 1/10 after 12 and did not
complete f'up.
Satterﬁeld (1999) ↓BAI WG: BAI pre-CBT 10, mild; 0 for the last four months of
therapy, (no multiple/stable baseline using BAI, raw data
not presented)
None.
Treatments that target speciﬁc anxiety disorders in a BPSD population (N = 7)
Baer et al. (1985) Reported
↓obsessions, ↓compulsions
No raw scores reported. None
Hamblen et al. (2004) ↓CAPS, ↓BPRS Total CAPS score, pre 57; post 8; 3 m f'up 9. None
Lu et al. (2009) ↓PCL⁎⁎⁎, ↓PDS⁎⁎, ↓BPRS⁎⁎⁎ WG: PCL diagnosis rates, pre 100%; post 69%; 3 m 33%;
6 m, 58%.
PDS diagnosis rates, pre 100%; post 89%, χ2 ns; 75%,
p = .01; 67%, p = .007.
Total PDS score pre, 35; post, 24, p = .002; 3 m, 19,
p b .001; 6 m, 17, p b 001.
Total PCL score pre, 59; post, 51, p = .02; 3 m, 44,
p = .004; 6 m, 48, p = .01.
Deﬁned as missing more than half the sessions. 5/
19 (26%) dropped out. 2 (11%) further lost to f'up;
one due to incarceration, and another due to
service discontinuation
Mueser et al. (2007) ↓PCL diagnosis⁎⁎⁎
↓PCL total⁎⁎⁎
WG: mean PCL score, pre 64; post 52; 3 m 52; last follow-
up 53, all p b .001.
Diagnosis rates pre 100%; post 76%; 3 m 77%; 6 m 80%, all
p b .05
Deﬁned as missing more than half the sessions.40/
80 (50%) dropped out of which 12 attended no
sessions. Outcome data available for 18–31
treatment completers, and 0–9 dropouts.
Mueser et al. (2008) ↓CAPS diagnosis, ↓CAPS total⁎⁎,
↓BAI⁎⁎
BG: diagnosis rates pre 100% CBT vs. 100% TAU; post 67.7%
vs. 77.8%; 3 m 63.3% vs. 77.1%; 6 m 72.7% vs. 85.0% ns.
Participants with CAPS N 65 at intake (N = 78) post 70.8%
CBT vs. 90.0% TAU; 3 m 68.2% vs. 92.3%; 6 m 78.3% vs.
88.2%, p = .02, large effect size.
Total CAPS score pre 74 CBT vs. 76 TAU; post 56 vs. 68; 3 m
55 vs. 65; 6 m 57 vs. 71, p = .005 large effect size.
BAI pre 48, CBT vs. 50, TAU; post 43 vs. 46; 3 m 41 vs. 48;
6 m 44 vs. 48, p = .03, large effect size
Deﬁned as missing more than half the sessions.
CBT: 10/54 (19%) dropped out of which 2 attended
no sessions after randomisation. A further 11 (20%)
in each group lost to f'up. Outcome data available
for 20–35/54 TAU and 30–33/54 CBT.
Rosenberg et al. (2004) ↓CAPS total⁎⁎⁎, ↓CAPS diagnosis,
↓BPRS⁎
WG: Total CAPS score; pre, 71; post 53; 3 m 48;
t(11) = 4.87, p b .001.
Diagnosis rates pre 100%; post 64%; 3 m 50%.
Total dropout 3/22 (14%). Deﬁned as missing more
than half the sessions. A further 6/22 (27%) were
lost to f'up. Full data available for 12 participants.
Thienot et al. (2013) ↓PSWQ,
↓QIA, ↓BAI
WG: SCID diagnosis rates pre 100%; post 25%.
BAI scores baseline 25, moderate; pre 20; post 10; 4 m 7
non-clinical.
Somatic symptoms QIA: baseline 31; pre 26; post 23; 4 m
21.
Cognitive symptoms PSQW: baseline 60; pre 55; post 49;
4 m 54.
None
Treatments that target BPSD symptoms only and report anxiety outcomes (N = 8)
Da Costa et al. (2011) ↓BAI⁎⁎⁎ BG: baseline 18.6 CBT, moderate, vs. 8.0 TAU, non-clinical,
p = 0.096.
WG: CBT pre 19, moderate; post 7, non-clinical,
p b 0.0005. Control pre 8, non-clinical; post 6, non-clinical,
p = .234.
4 dropped out (2 from each group); 3 due to
hospitalisation, 1 preferred individual therapy. Data
for 4 dropouts not complete.
Docteur et al. (2013) ↓HAM-A⁎ WG: CBT mean HAM-A pre 9.6; post 8.21 Cohen's d = .38,
t = 2.36, df = 40, p = .012 (whether pre-post or pre-f'up
not speciﬁed) TAU p N .25, U value not stated. Raw scores
not provided for TAU.
11 lost to f'up, all CBT group.
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Table 2 (continued)
Results Scores Dropouts
Treatments that target BPSD symptoms only and report anxiety outcomes (N = 8)
Docteur et al. (2007) =HAM-A WG: pre 8.62; post 9.00 ns 2 did not attend the group, 3 dropped out early. 5
dropouts were not reassessed. n = 7 analysed.
Proudfoot et al. (2012) GADS:
↓WG, =BG
WG: signiﬁcant improvement in GADS across the whole
sample (p b .01), but no signiﬁcant between-group
differences or interactions.
Raw scores were not presented. Peer support increased
adherence, but this did not affect outcome.
Of N = 419 randomised, 118 (28%) dropped out/
withdrew and a further 132–142 (32–34%) lost to
f'up. BEP 45/141(32%) dropped out/withdrew, and
a further 48–52 (34-37%) lost to f'up. BEP + IS 32/
139 (23%) dropped out/withdrew, 42–44 (30–32%)
lost to f'up. Control 41/139 (29%) dropped out/
withdrew, 42–46 (30–33%) lost to f'up.
Totterdell et al. (2012) ↓Anxious 1-9 scale⁎⁎. Anxiety and variation fell: baseline, 5.08, sd 1.33; therapy,
3.87, sd 1.36; follow-up, 2.23, sd 0.63. ANCOVAs signiﬁcant
differences baseline vs. during/after therapy; partial
η2 = .12, F(2, 1195) = 81.51, p b .01. Signiﬁcant
interaction between time-of-day and stage indicated less
deviation each day (partial η2 = .05, F(6, 1195) = 10.10,
p b .01); and less within-day variability (partial η2 = .13,
F(2, 318) = 23.79, p b .01)
None
Van Gent et al., 1988;
Van Gent & Zwart,
1993a
=STAI-T,
=STAI-S,
=SCL anxiety, =SCL ag'phob
STAI-S; pre, 45 psychoed, vs. 41 WL; post, 43 vs. 39; 3 m
44 vs. 42; 15 m, 43 vs. 39.
STAI-T; pre, 48 vs. 42; post, 44 vs. 41; 3 m 44 vs. 41; 15 m,
43 vs. 42.
SCL ag'phob; pre, 9 vs. 9; post — no data; 3 m, 9 vs. 9;
15 m, 9 vs. 9.
SCL anxiety subscale; pre, 16 vs. 14; post — no data; 3 m,
16 vs. 14; 15 m, 15 vs. 14
Deﬁned as attending less that 8 group sessions,
stopped taking lithium, or were admitted. 4/34
(12%) dropped out; 2/20 from the treatment group
(due to a vacation and feeling too well/sufﬁciently
informed) and 2/14 dropped out of the control
group (one was admitted, the other stopped taking
lithium). Further participants lost to f'up not clearly
reported.
Van Gent and Zwart
(1993b), Van Gent
(2000)
↓STAI-T STAI-T pre 48 10-session group vs. 45 ﬁve-session group;
3 m 44 vs. 49; 15 m 42 vs. 45
Deﬁned as stopping more than one group session
before the end. 3/35 (9%) dropped out, of which 2/
20 (10%) from group therapy and 1/15 (7%) from
education group. Further participants lost to f'up
not clearly reported.
Williams et al. (2008) WG:
=BAI MBCT, ↑BAI TAU
Time ∗ group ∗ condition interaction, F(1,41) = 7.55,
p = .009.
Group ∗ condition interaction, F(1,41) = 5.63, p = .032.
WG: (BPSD patients, MBCT condition) BAI, pre: 13, mild;
post, 7, non-clinical, ns. (TAU condition) pre, 11, mild;
post, 21, moderate, p = .004
3 BPSD participants started treatment did not
complete ﬁnal follow-up. Timing of dropout not
speciﬁed.
Note. ↑Increase in anxiety scores, =No change, ↓Decreased anxiety.
ns = non signiﬁcant.
ANCOVA = analysis of covariance, BEP = bipolar education program, BG = between-groups, CBT = cognitive behavioural therapy, F'up = follow-up,MBCT = mindfulness-based cog-
nitive therapy, psychoed = psychoeducation, WBT = wellbeing therapy, WG = within-groups, WL = Waiting list control.
Measures: BAI = Beck Anxiety Inventory, BPRS = Brief Psychiatric Rating Scale, CAPS = Clinician Administered PTSD Scale, CIDI-AUTO = computerised Composite Interna-
tional Diagnostic Interview (Peters & Andrews, 1995; World Health Organisation, 1995); DASS = Depression Anxiety Stress Scales (Crawford & Henry, 2003; Lovibond & Lovibond, 1995);
GADS = Goldberg Anxiety and Depression Scale, HAM-A = clinician-rated Hamilton Anxiety Rating Scale, MADRS = Montgomery Åsberg Depression Rating Scale (Hamilton, 1959);
PCL = PTSD Checklist (Blanchard et al., 1996); PDS = Posttraumatic Diagnostic Scale (Foa, 1995); PSS14 = Perceived Stress Scale (Paulhan & Bourgeois, 1998); PSWQ = Penn State
Worry Questionnaire (Meyer, Miller, Metzger, & Borkovec, 1990); QIA = Worry and Anxiety Questionnaire (French) (Dugas et al., 2001); SADS = Schedule for Affective Disorders and
Schizophrenia (Spitzer & Endicott, 1979); SCID = Structured Clinical Interview for DSM, SCL = Symptom Checklist, Ag'phob = Agoraphobia subscale, STAI-S/T = State Trait Anxiety
Inventory − State / Trait version (van der Ploeg, 1982).
∞ Trend level p b .1, pertaining to the signiﬁcance of last follow-up reported.
⁎ Signiﬁcant to p b .05, pertaining to the signiﬁcance of last follow-up reported.
⁎⁎ Signiﬁcant to p b .01, pertaining to the signiﬁcance of last follow-up reported.
⁎⁎⁎ Signiﬁcant to p b .001, pertaining to the signiﬁcance of last follow-up reported.
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Three uncontrolled, open studies were identiﬁed. Two had follow-
ups; 6 months (Dusser et al., 2009), and 8 weeks, (Reilly-Harrington
et al., 2007), and one did not (Miklowitz et al., 2009).
Dusser et al.'s (2009)N=10pilot study applied a novel “stressman-
agement” therapy for BP-I and II, using CBT and decentring principles,
including regular relaxation, breathing, self-soothing, and “concentra-
tion and directed attention” exercises. Within-group reductions in
clinician-reported anxiety were signiﬁcant. Self-reported stress im-
proved slightly and signiﬁcantly, whereas self-reported state anxiety
did not.
Reilly-Harrington et al.'s (2007) N = 10 pilot applied CBT to rapid
cycling BP-I and included ﬁve sessions of CBT anxiety management.
Seven of those who started had comorbid anxiety, but diagnostic inter-
views were not repeated post-therapy. Data are presented only for the
six treatment completers. Self-rated anxiety symptoms improved, and
were maintained at eight week follow-up, but the mean decrease was
not statistically signiﬁcant.Miklowitz et al. (2009) piloted (withN=22) an adapted eightweek
MBCT course, similar to Perich et al. (2013). The targetwas BPSD relapse
prevention (I and II), with anxiety symptoms as a secondary outcome
measure. There were small effect size improvements from pre- to
post-treatment in self-reported anxiety symptoms, but no tests of sta-
tistical signiﬁcance due to the low numbers, and no follow-up.3.2.3. Single-case experimental design studies
One study (Satterﬁeld, 1999) is a single-case, experimental design in
rapid cycling BP-I, however anxiety data were only collected pre- and
during the treatment phase (no baseline). It applied a novel CBT inter-
vention for BPSD symptoms, which included a) prediction andmonitor-
ing, b) prevention, and c) treatment/stabilisation. Therapy also included
identifying idiosyncratic sources of stress, and subsequent systematic
desensitisation and anxiety training, with the aim of preventing BPSD
episode onset. Self-reported anxiety symptoms reduced over the course
of therapy.
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The addition of an anxiety component to existing CBT treatments for
BPSD appears effective in reducing anxiety scores and comorbid anxiety
diagnosis rates. Two large, good quality RCTs with extensive follow-ups
found that comorbid anxiety rates in an unmedicated cyclothymia pop-
ulation (Fava et al., 2011), and anxiety symptoms in refractory BPSD
(González-Isasi, et al., 2010; González Isasi, et al., 2012), reduced signif-
icantly following CBT. Results of a single-case (Satterﬁeld, 1999) and
pilot study (Reilly-Harrington et al., 2007) are also promising for CBT
for rapid-cycling BP. Generalisability may be limited by the rapid-
cycling population, however studies of rapid cycling BPSD may also be
helpful for assessing the impact of treatment. When episodes are less
frequent a much longer follow-up is needed to capture improvement
in terms of acute relapse. When episodes are infrequent, inter-episode
variability can also be monitored (Bonsall, Wallace-Hadrill, Geddes,
Goodwin, &Holmes, 2012). These smallN and pilot studieswarrant rep-
lication in other BPSDs.
CBT for non-speciﬁc “stress” has some positive outcomes, but these
appear less clear than those derived from a speciﬁc cognitive model of
anxiety. As yet, the evidence appears hard to interpret for adapted
MBCT although suggestive of small effect size improvements.
The evidence gathered suggests that the addition of CBT anxiety
components to standard treatments for BPSD may provide a useful
route for treatment development. However, it is not possible to draw
ﬁrmconclusions about clinical efﬁcacy from the small number of studies
currently available. Although it has not been possible to systematically
compare these here, the studies reviewed also found positive outcomes
for mood symptoms; the potential beneﬁt on depressive and manic
symptoms of anxiety treatment would be worth exploring further.
3.3. Treatments that target speciﬁc anxiety disorders in a BPSD
population (N = 7)
3.3.1. Randomised controlled trials
Only one RCT was identiﬁed (Mueser et al., 2008), which applied
CBT for PTSD in a “severe mental illness” [SMI] population, which in-
cludes major mood disorders (including BPSD), psychotic disorders,
and axis II personality disorders. The adapted CBT protocol emphasises
integration with case management and cognitive restructuring tech-
niques rather than trauma exposure, thought to be more palatable and
safe for this client group (Mueser, Rosenberg, Jankowski, Hamblen, &
Monica, 2004; Mueser, Rosenberg, & Rosenberg, 2009). Of N = 108,
25 participants had BPSD (type not speciﬁed). The between-group
change on diagnosis between CBT and TAU was not signiﬁcant for the
whole sample using the Clinician-Administered PTSD Scale [CAPS]
(Blake et al., 1995), although reached statistical signiﬁcance for those
with CAPS N 65 (n = 78) at intake. PTSD symptoms improved with a
large effect size, as did self-reported anxiety symptoms, although
these remained in the severe range. Results were not presented sepa-
rately for the different diagnostic groups.
3.3.2. Uncontrolled/non-randomised pilot studies
Three uncontrolled studies provide further preliminary evidence for
Mueser et al.'s (2004) adapted CBT protocol for PTSD also in SMI popu-
lations. Rosenberg et al.'s (2004) pilot ofN=13 includes two treatment
completers with BPSD (type not speciﬁed). Using the CAPS, there were
statistically signiﬁcant within-subjects improvements in self-reported
PTSD symptoms and reductions in diagnosis rates. In an ethnically and
culturally diverse urban population, Lu et al. (2009) reported statistical-
ly signiﬁcant within-subjects improvements in PTSD symptoms and di-
agnosis rates. The proportion (of N= 14) with BPSD was not reported.
In a group format, Mueser et al. (2007) reported statistically signiﬁcant
within-subjects improvements on PTSD symptoms, and the slight re-
duction in diagnosis rates was statistically signiﬁcant. Seven (of N =
80) had BPSD (type not speciﬁed) but results were not presented sepa-
rately for the different diagnostic groups.3.3.3. Single-case experimental design studies
One study uses an N= 4, multiple-baseline, single-case experimen-
tal design (Thienot et al., 2013). Three of the four participants with BP-I,
II or NOS no longer met diagnostic criteria for GAD (onemet criteria for
anxiety NOS with high worry) following an established CBT manual
(Dugas, 2004). There were reductions in self-reported symptoms of
anxiety, somatic symptoms, andworry (albeit the latter not consistently
maintained).
3.3.4. Case studies
Two case studieswere identiﬁed, but they lack a baseline and cannot
be considered experimental. Hamblen et al. (2004) described an N= 1
case study from Rosenberg et al.'s (2004) pilot (above), who recovered
from PTSD by three month follow-up. Baer et al. (1985) reported an
N= 2 case study of ERP for OCD with BP-I and mania-only in an inpa-
tient setting. The author emphasised the medical stabilisation of mood
symptoms required prior to the intensive ERP for OCD. Checking behav-
iour and obsessions reportedly reduced, and functioning and activities
increased, however no formal measures or outcomes (e.g. time spent)
are reported.
3.3.5. Summary of treatments for a speciﬁc co-morbid anxiety disorder
Adapted CBT for PTSD in BPSD appears promising. The only RCT
(Mueser et al., 2008) ﬁnds modest reductions in diagnosis rates, per-
haps explained by the control condition being a specialist multidisci-
plinary intervention that may include medication and “supportive
counselling”. However, it is noted that only approximately a quarter of
this sample were BPSD, and results are not reported by diagnostic
group, although the authors found no signiﬁcant differences in im-
provement between the diagnostic groups (Mueser, personal commu-
nication, 22nd December 2011). Further research with BPSD-only
populations would be welcome. Uncontrolled studies found signiﬁcant
reductions in self-reported symptoms. These studies beneﬁt from ﬁdel-
ity checks, and generalization is aided by the treatment having been de-
livered by local trained clinicians, rather than specialists.
One preliminary study suggests that CBT treatment for GAD in
euthymic BPSD patients may be effective, and larger feasibility studies
are indicated. The results beneﬁt from the experimental design, which
provides a within-subject control. Interestingly, the participant who
beneﬁtted least had an additional diagnosis of social anxiety. Traditional
ERP for OCD may be helpful, although the results should be interpreted
with caution given themethodological limitations. Given developments
in OCD treatment, a more recent CBT approach – which incorporates
cognitive elements in addition to ERP – may be more appropriate
(NICE, 2005a). Studies that apply evidence-based protocols for other
anxiety disorders to people with BPSD would be welcome, such as
panic with/without agoraphobia, social anxiety, and phobias. Further
research should also seek to gather information on the subsequent ef-
fect of anxiety treatment on mood symptoms during an extended
follow-up period since none of the current studies report on this.
3.4. Treatments that target BPSD symptoms only and report anxiety
outcomes (N = 8)
3.4.1. Randomised controlled trials
Three RCTs were identiﬁed, although only one includes an active
control condition, and participants blind to condition (Proudfoot et al.,
2012). The other two use TAU as a comparison. Two include a
6 month follow-up (Da Costa et al., 2011; Proudfoot et al., 2012).
Proudfoot et al.'s (2012) N = 407 RCT applied computerised
psychoeducation in a sample of recently diagnosed BPSD (type not
speciﬁed) participants, and collected data on anxiety symptoms. The Bi-
polar Education Program [BEP] is a computerised, non-interactive,
audio-visual, psychoeducation programme with no therapist contact.
There were three groups; BEP alone was compared to BEP plus emails
from “Informed Supporters” [IS] and to an active control. ISs were
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emails per week. Participants were recruited within a year of diagnosis
(BPSD type not speciﬁed), and therefore not necessarily between epi-
sodes; only 48.16% were euthymic at intake. Information on comorbid-
ities was not gathered. Drop-out was high, with 66% providing data at
post-treatment and six-month follow-up. Descriptive statistics showing
mean scores on outcomemeasures are not provided. There were signif-
icant within-subject improvements in anxiety and depression, but no
signiﬁcant between-group differences or interactions. Peer support in-
creased adherence, but this did not affect outcome. The authors posit
that non-speciﬁc factors and self-monitoring common to all three con-
ditions (i.e. use of an active control), lack of power due to drop-out, or
the failure to exclude those in episode masked any potential effect.
The negative ﬁnding in this large RCT suggests that computer-based
psychoeducation following diagnosis, with or without support, does
not appear to reduce anxiety or other symptoms compared to reading
information online.
Da Costa et al.'s (2011) N= 41 RCT compares group CBT, which in-
cluded family members in psychoeducation sessions, to TAU. Thirty per-
cent of participants (BP-I or II) had an axis I comorbidity (not speciﬁed),
although axis I “severe psychiatric disorder” (not operationalised) and
axis II comorbidities were excluded, as were participants who required
a change of medication during the study. Within-group pre-post im-
provements in self-reported anxiety symptoms were highly signiﬁcant
in the CBT group and non-signiﬁcant for the control group. Data from
the 6-month follow-upwere not reported. This study suggests that stan-
dard CBT for BPSDmay also reduce anxiety but direct comparison to TAU
is lacking. Thus, interpretation must be cautious due to methodological
and reporting issues, critically the presentation of only within-group
changes (i.e. no formal between-group comparisons of outcome), small
and uneven group numbers, and lack of blinding and follow-up data.
OfN=55mood disorder participants inWilliams et al.'s (2008) RCT,
n = 14 had BPSD (type not speciﬁed) and the rest (unipolar) depres-
sion, distributed evenly between conditions. The standard 8 week
MBCT group treatment was compared to TAU using a waitlist [WL] con-
dition, and anxiety symptom data were collected. Researchers were
blind to assignment, and all outcome data were by self-report. Amongst
the participants with BPSD, there was a signiﬁcant increase in self-
reported anxiety symptoms from pre- to post-treatment in the TAU
condition, but no signiﬁcant change in theMBCT condition. The authors
suggest that this may indicate a protective effect of MBCT on anxiety.
However, the study was designed to establish feasibility of MBCT in re-
mitted patientswithmood disorders and a history of suicidal ideation or
behaviour, rather than efﬁcacy of MBCT in BPSD speciﬁcally. Thus the
sample size is small and the results must be regarded as preliminary.
3.4.2. Uncontrolled/non-randomised pilot studies
Four studies were identiﬁed; one was uncontrolled (Docteur et al.,
2007), two compared treatment with a WL control condition (Van
Gent et al., 1988;Docteur et al., 2013), and one compared two treatment
groups without random allocation (Van Gent, 2000; Van Gent & Zwart,
1993b). Two have a follow-up of 15 months (Van Gent et al., 1988; Van
Gent, 2000) and one of 5–9 months (Docteur et al., 2013).
Docteur et al.'s (2007) N = 12 uncontrolled pilot study presents
complete data for n = 7. Treatment was group CBT and participants
had BP-I according to diagnostic criteria (assessment method not spec-
iﬁed). Comorbid anxiety and personality disorders were allowed but
numbers are not reported. There was no signiﬁcant pre-post change in
clinician-rated anxiety, and no follow-up.
Docteur et al.'s (2013)N=73 study compared groupCBT in BP-I to a
WL control groupwithout randomallocation. Improvement in clinician-
rated anxiety was statistically signiﬁcant in the CBT group but not in
TAU. This paper suggests that anxiety reduces following group CBT,
but the results must be interpreted with caution due to methodological
limitations: time to follow-up differs; group sizes are unequal; only
within-group differences are reported (i.e. no between-groupcomparison), using different analytic strategies (parametric vs. non-
parametric); and assessor blinding (for clinician-rated assessment) is
not speciﬁed.
Van Gent, Vida, & Zwart's (1988) N = 34 study compares group
psychoeducation to a WL control condition, method of allocation not
speciﬁed. Anxiety symptoms were unchanged, and psychoeducation
did not reduce anxiety compared to WL control condition.
Data from the treatment described in the above study is then com-
pared in two papers (Van Gent, 2000; Van Gent & Zwart, 1993b) to
data from a condensed “ultra-short” version with additional written
materials (ﬁve sessions), precluding random allocation. There was no
signiﬁcant difference in anxiety outcomes between the 10-session and
ultra-short conditions. Overall, these psychoeducation groups do not
appear to improve anxiety signiﬁcantly.3.4.3. Single-case experimental design studies
Totterdell et al.'s (2012) N = 1 “intensive time-sampling,”
multiple-baseline, single-case experimental design adapted Basco
and Rush's (2005) CBT protocol for cyclothymia. Anxiety was mea-
sured using a scale of one (not at all) to nine (a great extent)
(Matthews, Jones, & Chamberlain, 1990) four times daily for
51 weeks; ﬁve weeks baseline, 35 weeks therapy, and 11 weeks
follow-up. It was hypothesised that anxiety would improve, al-
though it was not directly targeted in treatment. Anxiety and varia-
tion therein – as assessed by standard deviations – improved
signiﬁcantly during/after therapy compared to baseline. Improve-
ment on all measures was mediated by a subjective measure of cog-
nitive control, consistent with the Mansell et al. (2007) model of BP.
This study suggests that targeting mood stability can improve anxi-
ety, and identiﬁes a possible mechanism for change.3.4.4. Summary of treatments that target BPSD symptoms only
There is no evidence from the studies reviewed here that
psychoeducation alone reduces anxiety in BPSD. Individual CBT for cy-
clothymia appeared to reduce anxiety in a single-case design and war-
rants further research. One RCT found individual CBT for BP-I and II
that included family members signiﬁcantly reduced anxiety scores. Re-
sults from non-controlled and/or non-randomised studies ﬁnd at best
modest results for group CBT for BPSD. The subgroup of BPSD patients
in an RCT ofMBCT showed no signiﬁcant reduction in symptoms of anx-
iety following MBCT, but did not show the increase in anxiety found in
BPSD patients in the TAU arm.4. Discussion
This paper collates and critically evaluates existing research into
psychological treatments for anxiety in BPSDs. Anxiety symptoms and
comorbidity are common in BPSD and confer poor outcomes in several
domains. Thus, treating anxiety in BPSD may reduce distress and im-
prove outcomes. Clearly the literature is in its infancy, but nevertheless
offers useful insights for clinicians and researchers.
All studies but one (Proudfoot et al., 2012) appear to apply treat-
ment inter-episode (i.e. between acute episodes of depression/
mania), but the deﬁnition of euthymia varies and a direct compari-
son between studies is not possible. This review focuses only on anx-
iety symptoms, and the relationship between anxiety and residual
mood symptoms remains to be examined. Future studies should
seek to gather parallel data to elucidate the links between anxiety,
inter-episodic mood symptoms, and treatment. This could be perti-
nent to the development of speciﬁc models of BPSD anxious distress,
and further speciﬁcation of the time course of mood instability and
its link to anxiety may aid the development of effective treatments
(Bonsall et al., 2012).
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The studies reviewed above are extremely heterogeneous, in terms
of patient characteristics, treatments applied, design, and outcome
measurement, and this limits the extent to which clear clinical implica-
tions can be drawn. Therefore we may have to conclude that it can be
useful to target anxiety in bipolar disorder via a psychological treatment
approach, but that at present it is not clear how best to do so. Based on
the small number of available RCTs, CBTwith speciﬁc additional compo-
nents targeted at managing anxiety appears to have the most support.
The possibility of reducing anxiety in BPSD via a speciﬁc anxiety
component is promising given the paucity of pharmacological alterna-
tives to treat anxiety in this patient group (see earlier). Indeed, pharma-
cological management of anxiety symptoms in BPSD can be complex
and include the use ofmultiple drugs, thus increasing the risk of physical
side effects (Goodwin et al., 2009). This could be minimised if anxious
distress was instead reduced by effective psychological interventions.
Therefore successful psychological treatment approaches for anxiety in
BPSD are likely to have a positive impact on the general long termman-
agement of the disorder. In fact, they could be a crucial advance in the
treatment of populations presentingwith particularly high levels of anx-
iety and for whom pharmacological interventions are most controver-
sial, such as youth with BPSD.
All the studies presented here applied treatment betweenmood ep-
isodes and in the presence of medication, suggesting that a psychologi-
cal approach to anxiety could be added to an existing treatment regime.
As the presence of anxiety has been shown to also have a direct negative
impact on adherence to pharmacological treatment (Perlis et al., 2010),
targeted psychological interventions for anxiety might also improve
medication compliance and thus lead to better prognosis, although
this remains to be assessed.
4.2. Research implications
While small N studies are appropriate at an early stage in treatment
development, future studies should consider the use of more formal
study designs and analytic strategies. More rigorous studies are re-
quired to further the ﬁeld. For example, data on safety, acceptability
and feasibility has not been systematically collected except by a handful
of studies (e.g. Rosenberg et al., 2004); future studies should collect and
report this (Dimidjian & Hollon, 2010).
The phenomenology and treatment of anxiety in different stages of
BPSD may be distinct. Although it is not stated, most studies included
in this review can be thought of as treating residual phase symptoms
(Cosci & Fava, 2012) rather than prodromal or acute phases. Future
studies could use these deﬁnitions to specify their target population,
and to compare the effectiveness of applying treatments during differ-
ent phases. As already mentioned, research is especially warranted for
prodromal stages of BPSD and youth populations, where anxiety is
prominent and there is a particular lack of available interventions
(Kapczinski et al., 2014).
It would be valuable for treatment research into BPSD to include
measures of anxiety as standard. Measures should be repeated at regu-
lar intervals to allow for the detection of change. Given the research sug-
gesting a potentially reciprocal relationship between anxiety and mood
symptoms in BPSD (Deckersbach et al., 2013; Holmes et al., 2011), it
would be useful to also research the effect of a speciﬁc anxiety-
focussed treatment and its impact on mood symptoms. Anxiety may
also be a key mediator of instability in BPSD (Holmes et al., 2008), and
statistical analyses would be useful to explore how mood and anxiety
symptoms may reciprocally affect each other (c.f. Maguire, McCusker,
Meenagh, Mulholland, & Shannon, 2008).
Given the considerable heterogeneity of treatment approaches avail-
able, an important goal for future research would be to identify which
speciﬁc treatment components or techniquesmay be effective in reduc-
ing BPSD anxiety, and their mechanisms of change, as this would allowdevelopment of briefer, more focussed, interventions (cf. Geddes &
Miklowitz, 2013). The available evidence suggests that including a treat-
ment component with a speciﬁc anxiety focus into CBT approaches is
helpful. CBT approaches may have several key core features, such as
having a structured, problem-focused and action-oriented approach,
formulation, and the systematic application of cognitive and behaviour-
al treatment techniques. However, there is also considerable heteroge-
neity, for example in the kinds of techniques that can be used within
this framework, and future work should seek to detail the speciﬁc
anxiety-focussed techniques used. Currently it is unclear how to maxi-
mize the effectiveness of an anxiety-focussed approach in BPSD. It
may be important to develop and test techniques designed speciﬁcally
around the phenomenology of BPSD anxiety, rather than only importing
modules from formulations of other axis 1 disorders, as has been sug-
gested for BP depression (Mansell, Colom, & Scott, 2005). Such a treat-
ment development process would beneﬁt from the identiﬁcation of
BPSD-speciﬁc cognitive processes related to anxiety in this population,
in order to provide targets for a focussed therapy.
For example, there is emerging evidence for a bias towards elevated
mental-imagery based processing in BPSD (e.g. Gregory, Brewin,
Mansell, & Donaldson, 2010; Gruber, Harvey, & Johnson, 2009; Hales,
Deeprose, Goodwin, & Holmes, 2011; Holmes et al., 2011; Ivins, Di
Simplicio, Close, Goodwin, & Holmes, 2014), which has been
hypothesised to play a key role in BPSD anxiety and mood instability
(Holmes et al., 2008). For anxiety disorders in which problematic men-
tal images are thought to play a central role in maintenance of distress
(e.g. ﬂashbacks in PTSD; Ehlers & Clark, 2000), working with these im-
ages to reduce their impact is a key part of many successful treatment
protocols. Thus, one possibility is that mental imagery-based treatment
techniques developed in the context of CBT for anxiety disorders (e.g.
Holmes, Arntz, & Smucker, 2007) may prove useful for anxiety BPSD.
However, these techniques may also (as noted above) require adapting
for people with BPSD and the nature of their problematic imagery. One
example might be to speciﬁcally tackle vivid intrusive imagery that has
been found to be elevated in bipolar disorder and linked tomood insta-
bility (Holmes et al., 2011), and to which thosewith hypomanic experi-
ence are vulnerable (Malik, Goodwin, Hoppitt, & Holmes, 2014). There
are likely to be other cognitive processes that could also offer targets
for treatment innovation. Identifying and characterising such cognitive
processes in BPSD and their relation to anxiety and mood instability
could present a useful step forward in guiding development of more ef-
fective BPSD-tailored approaches (Geddes & Miklowitz, 2013).
4.3. Limitations
In the current review, there is a risk of selection bias due to searching
only titles and abstracts for “anxiety” or related terms; studies that
found signiﬁcant results may have been more likely to report anxiety
measures in the abstract, whereas studies with negative ﬁndings on
anxiety measures may have omitted tomention anxiety in the abstract.
This review aimed to reduce bias by including papers published in
any language; though relied on a supplementary abstract or title in En-
glish. Four studies in French are included (Docteur et al., 2007; Dusser et
al., 2009; Thienot et al., 2013; VanGent, 2000). This reviewaimed to col-
late all relevant studies, without limitation on year of publication,meth-
odology, sample size, or other stipulations, which allows as thorough a
review as possible. However, it prevents formal synthesis of the data.
Investigating the effect of treatments for anxiety on the stability of
BPSD symptoms and on long-term relapse rates was outside the scope
of this review, and would be a valuable contribution for future research
(e.g. preliminary studies such as Fava et al., 2001).
5. Conclusions
Research investigating psychological treatment for anxiety in BPSD is
much needed yet still in its infancy; few studies exist and the ﬁeldwould
31H.J. Stratford et al. / Clinical Psychology Review 35 (2015) 19–34beneﬁt from more RCTs with adequate power. However, studies to date
that have applied psychological therapy inter-episode (i.e. between
acute episodes of mania or depression) have found beneﬁts for anxiety,
even if modest. There is no empirical basis to suggest that psychological
treatment is harmful or ineffective in this population. These ﬁndings help
to establish a role for existing psychological interventions for anxiety,
and the need for development of tailored psychological interventions
for anxious distress in BPSD. Future research should focus on identifying
the speciﬁc treatment components responsible for reducing anxiety in
BPSD, and the key psychological processes to target via therapy.
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spectrum disorder”).ti,ab585862 AMED, EMBASE, HMIC,
MEDLINE, PsycINFO, BNI,
CINAHL, HEALTH BUSINESS
ELITE(anxiety OR anxious).ti,ab 4098933 AMED, EMBASE, HMIC,
MEDLINE, PsycINFO, BNI,
CINAHL, HEALTH BUSINESS
ELITE(psychoeducation OR psycho-
therapy OR “psychological thera-
py” OR “cognitive therapy” OR
“cognitive behavio* therapy” OR
“CBT” OR “family therapy”).ti,ab1926614 AMED, EMBASE, HMIC,
MEDLINE, PsycINFO, BNI,
CINAHL, HEALTH BUSINESS
ELITE1 AND 2 AND 3 2885 AMED, EMBASE, HMIC,
MEDLINE, PsycINFO, BNI,
CINAHL, HEALTH BUSINESS
ELITEDuplicate ﬁltered: [1 AND 2
AND 3]288
109 unique
results
179 duplicate
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